Pharma-Bio Serv (PBSV) Liabilities and Shareholders Equity (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $11.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 17.29% year-over-year to $11.5 million; the trailing twelve-month figure through Apr 2026 stood at $52.3 million (down 16.46% YoY), and the FY2025 full-year result was $13.7 million, down 16.2% from the prior year.
• Liabilities and Shareholders Equity eased to $11.5 million in Q2 2026 per PBSV's latest filing, from $13.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $22.9 million in Q1 2023 and bottomed at $11.5 million in Q2 2026.
• Historically, Liabilities and Shareholders Equity has averaged $17.6 million across 5 years, with a median of $18.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity fell 28.91% in 2022, then increased 3.74% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $20.7 million in 2022, then declined by 3.63% to $19.9 million in 2023, then dropped by 18.14% to $16.3 million in 2024, then fell by 16.2% to $13.7 million in 2025, then fell by 15.77% to $11.5 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $11.5 million, $13.5 million, and $13.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.